Experimental and clinical results with intraperitoneal cisplatin.
Up to 30% of ovarian cancer patients with minimal residual disease may achieve a complete remission with intraperitoneal cisplatin therapy. This mode of therapy, however, is toxic and cumbersome. Sodium thiosulfate was shown to protect renal function, as well as lessen hematologic complications of cisplatin therapy. A major problem with cisplatin in terms of achieving maximal therapeutic dosages is neurotoxicity. Different platinum chemotherapeutic agents, pharmacodynamics, and pharmacokinetics of intraperitoneal administration, and rescue agents other than sodium thiosulfate are presently being investigated by The Netherlands Cancer Institute.
D000971:Antineoplastic Combined Chemotherapy Protocols; D002404:Catheterization / Q000009:adverse effects; D002408:Catheters, Indwelling; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007674:Kidney Diseases / Q000139:chemically induced; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010529:Peritoneal Cavity; D012086:Reoperation; D013885:Thiosulfates / Q000008:administration & dosage
D013885:Thiosulfates; C017717:sodium thiosulfate; D002945:Cisplatin